Infant, children and young people's experience of health careStatus:Awaiting developmentExpected publication date: TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Children and young people with disabilities and severe complex needs: integrated health and social care supportStatus:Awaiting developmentExpected publication date: TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years TSID 12049Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital support for children and young people with eating disorders:early value assessmentStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC